Prescriber

NHS England and the Department of Health and Social Care have published a delivery plan outlining commitments to tackle the 8am rush for GP appointments and make it easier for patients to get the help they need from primary care. The plan focuses on a much bigger role for pharmacists in managing patients’ common ailments, but does the already‐overstretched pharmacy sector feel supported enough to take it on?

Angela Dowden

Views on the delivery plan for recovering access to primary care

关于恢复初级保健服务可及性的交付计划的看法

Eptinezumab (Vyepti) is a new CGRP monoclonal antibody for migraine prophylaxis that is administered by intravenous infusion. This article discusses its place in therapy, clinical trial efficacy and adverse effects.

Steve Chaplin

Eptinezumab for the prophylaxis of migraine in adults

成人偏头痛预防中的依普利珠单抗

Unlike many other malignancies, mortality rates for pancreatic cancer have remained stubbornly stable, mainly reflecting the cancer's typically late presentation, ambiguous symptoms and a lack of research. However, scientists have now identified early biomarkers and patient risk factors that should help to detect this increasingly common malignancy while it remains curable.

Mark Greener

Pancreatic cancer: the insidious, deadly malignancy

胰腺癌：隐匿而致命的恶性肿瘤

The initial excitement inspired by the landmark clinical trials demonstrating the benefits of statins for the prevention of cardiovascular disease was soon dampened by reports of adverse events. Tolerability has remained a controversial topic ever since. However, recent studies suggest that most reported adverse effects of statins can be attributed to the nocebo effect.

Statins: 30 years after the landmark <scp>4S</scp> study

他汀类药物：标志性<scp>4S</scp>研究30年后

Professor Tony Avery OBE is a GP, National Clinical Director for Prescribing and Professor of Primary Health Care at the University of Nottingham. Here, he speaks to Joy Ogden about how his clinical practice and research on improving prescribing safety in primary care complement his leadership role in the implementation of the National Overprescribing Review.

Joy Ogden

Improving prescribing and patient safety in primary care

改善初级保健中的处方和患者安全

Cardiovascular disease (CVD) remains the second most common cause of death in England, after dementia and Alzheimer disease, causing a quarter of all deaths. Hypertension is the largest single known risk factor for CVD; however, as the condition rarely has noticeable symptoms, an estimated 4.2 million people in England are walking around with undiagnosed hypertension. This article presents how one primary care network (PCN), Nottingham West, is working in new ways to make a difference to the health of their local population about hypertension.

Clare Watson

Beth Rushton

Hypertension: a <scp>PCN</scp> Clinical Pharmacist‐led intervention

高血压：一项由<scp>PCN</scp>临床药师主导的干预措施

Given the myriad of available tests, guidelines and treatments, chronic infection with the hepatitis B virus (HBV) can seem daunting for the nonspecialist. However, its prevalence among some of the most vulnerable in society, the stigma surrounding it and its potential to lead to cirrhosis and hepatocellular carcinoma (HCC) make it crucial for the frontline primary care physician to understand.

Chris Harlow

Kosh Agarwal

The management of chronic hepatitis B

慢性乙型肝炎的管理

Phenibut is less frequently used in the UK compared with heroin, cocaine, crack, cannabis, ketamine or alcohol but is currently not covered by the UK drugs legislation. It is widely available on the internet, and its popularity is increasing, particularly among younger, internet‐savvy patients. This case describes a patient who developed psychosis during medically assisted withdrawal from phenibut.

Marcus Bicknell

Joshua Bachra

David Rhinds

Psychosis following phenibut‐assisted withdrawal

苯巴比妥辅助戒断后的精神病症状

The understanding of schizophrenia has remarkably expanded over the past few decades, moving beyond the dopamine hypothesis to encompass neurotransmitter interplays, structural brain changes and genetic and environmental determinants. This has led to innovations in therapeutic interventions that offer improved outcomes. This paper explores past and current treatments available for schizophrenia, the latest pharmacological advances and the significance of psychotherapeutic approaches.

Beryl Navti

Nik Nikolic

Current treatments in schizophrenia

精神分裂症的当前治疗方法

Ruxolitinib cream is licensed for the treatment of non‐segmental vitiligo with facial involvement in adolescents (≥12 years old) and adults. This article summarises its mechanism of action, the clinical trial evidence of efficacy and its place in therapy.

出版信息	出版商: Wiley-Blackwell Publishing Ltd，出版周期: ，期刊类型: journal，开源期刊: 否
基本数据	创刊年份: 2014，原创研究文献占比: ，自引率:， Gold OA占比:

Prescriber

期刊引文格式

有 1 位以上作者的期刊

有 2 位作者的期刊

有 3 位作者的期刊

有 5 位以上作者的期刊

书籍引用格式

学位论文引用格式

网页引用格式

专利引用格式

手工熬夜修改参考文献？研飞自动匹配期刊，一键轻松成稿，支持 Word/WPS

投稿经验分享